NCT02223260View on ClinicalTrials.gov

Tolerability , PK/PD and Safety of Dabigatran Etexilate Oral Liquid Formulation in Children < 1 Year of Age

PHASE2CompletedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

September 30, 2014

Primary Completion Date

January 31, 2016

Study Completion Date

February 29, 2016

Conditions
Venous Thromboembolism
Interventions
DRUG

dabigatran

Experimental dose chosen based on age and weight

Trial Locations (4)

Unknown

1160.105.10002 Boehringer Ingelheim Investigational Site, Ottawa

1160.105.10003 Boehringer Ingelheim Investigational Site, Montreal

1160.105.33001 Boehringer Ingelheim Investigational Site, Paris

1160.105.70005 Boehringer Ingelheim Investigational Site, Kazan'

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY

NCT02223260 - Tolerability , PK/PD and Safety of Dabigatran Etexilate Oral Liquid Formulation in Children < 1 Year of Age | Biotech Hunter | Biotech Hunter